JP2018521689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521689A5 JP2018521689A5 JP2018517674A JP2018517674A JP2018521689A5 JP 2018521689 A5 JP2018521689 A5 JP 2018521689A5 JP 2018517674 A JP2018517674 A JP 2018517674A JP 2018517674 A JP2018517674 A JP 2018517674A JP 2018521689 A5 JP2018521689 A5 JP 2018521689A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- sequence
- cell
- nucleic acid
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 39
- 102000037865 fusion proteins Human genes 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 239000012636 effector Substances 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 108020005004 Guide RNA Proteins 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 230000004807 localization Effects 0.000 claims description 8
- 108091033409 CRISPR Proteins 0.000 claims description 7
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 5
- 101710163270 Nuclease Proteins 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 230000008265 DNA repair mechanism Effects 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000008707 rearrangement Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 210000002308 embryonic cell Anatomy 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000004568 DNA-binding Effects 0.000 claims description 2
- 241000232299 Ralstonia Species 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108091006106 transcriptional activators Proteins 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 238000010459 TALEN Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 101100481002 Mus musculus Tff1 gene Proteins 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021079698A JP7170090B2 (ja) | 2015-06-17 | 2021-05-10 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181162P | 2015-06-17 | 2015-06-17 | |
| US62/181,162 | 2015-06-17 | ||
| PCT/US2016/037922 WO2016205554A1 (en) | 2015-06-17 | 2016-06-16 | Compositions and methods for directing proteins to specific loci in the genome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021079698A Division JP7170090B2 (ja) | 2015-06-17 | 2021-05-10 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521689A JP2018521689A (ja) | 2018-08-09 |
| JP2018521689A5 true JP2018521689A5 (enExample) | 2019-07-18 |
Family
ID=56292934
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517674A Ceased JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
| JP2021079698A Active JP7170090B2 (ja) | 2015-06-17 | 2021-05-10 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
| JP2021141109A Withdrawn JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021079698A Active JP7170090B2 (ja) | 2015-06-17 | 2021-05-10 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
| JP2021141109A Withdrawn JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11473082B2 (enExample) |
| EP (2) | EP3310909B1 (enExample) |
| JP (3) | JP2018521689A (enExample) |
| KR (1) | KR102637402B1 (enExample) |
| CN (1) | CN108026519A (enExample) |
| AU (2) | AU2016278226B2 (enExample) |
| CA (1) | CA2989827C (enExample) |
| DK (1) | DK3310909T3 (enExample) |
| ES (1) | ES2886599T3 (enExample) |
| PT (1) | PT3310909T (enExample) |
| WO (1) | WO2016205554A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2778033T3 (es) | 2012-11-16 | 2020-08-07 | Poseida Therapeutics Inc | Enzimas específicas de sitio y métodos de uso |
| KR102630014B1 (ko) | 2014-10-01 | 2024-01-25 | 더 제너럴 하스피탈 코포레이션 | 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법 |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| KR102588469B1 (ko) * | 2016-09-30 | 2023-10-11 | 포세이다 테라퓨틱스, 인크. | 변형된 줄기세포 기억 t 세포, 이의 제조 방법 및 사용 방법 |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
| SG10202109731YA (en) | 2017-03-13 | 2021-10-28 | Poseida Therapeutics Inc | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| AU2018299995B2 (en) * | 2017-07-11 | 2021-10-28 | Sigma-Aldrich Co. Llc | Using nucleosome interacting protein domains to enhance targeted genome modification |
| US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| WO2019126578A1 (en) * | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| WO2019246486A2 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| CN110938658B (zh) * | 2018-09-21 | 2023-02-07 | 中国科学院分子细胞科学卓越创新中心 | 一种抗体进化方法及其应用 |
| WO2020077360A1 (en) | 2018-10-12 | 2020-04-16 | Poseida Therapeutics, Inc. | Hematopoietic stem cell compositions, methods of making and method of use |
| CN113498439A (zh) | 2018-12-20 | 2021-10-12 | 波赛达治疗公司 | 纳米转座子组合物及使用方法 |
| WO2020160481A1 (en) * | 2019-02-01 | 2020-08-06 | The General Hospital Corporation | Targetable 3'-overhang nuclease fusion proteins |
| US20220204569A1 (en) * | 2019-04-09 | 2022-06-30 | Japan Science And Technology Agency | Nucleic acid-binding protein |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| AU2020342544A1 (en) | 2019-09-05 | 2022-03-24 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CN115135672A (zh) | 2019-12-20 | 2022-09-30 | 波赛达治疗公司 | 抗muc1组合物和使用方法 |
| US20230121433A1 (en) | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| WO2022087148A1 (en) | 2020-10-21 | 2022-04-28 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| WO2022087354A1 (en) * | 2020-10-23 | 2022-04-28 | Altius Institute For Biomedical Sciences | Cell permeable proteins for genome engineering |
| CN112750498B (zh) * | 2020-12-30 | 2022-06-24 | 同济大学 | 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法 |
| US20240060090A1 (en) | 2021-02-23 | 2024-02-22 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
| EP4297728A1 (en) | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| US20240424097A1 (en) | 2021-09-09 | 2024-12-26 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| AU2022360244A1 (en) | 2021-10-04 | 2024-04-11 | Poseida Therapeutics, Inc. | Transposon compositions and methods of use thereof |
| US20250099383A1 (en) | 2022-01-21 | 2025-03-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| WO2023164573A1 (en) * | 2022-02-23 | 2023-08-31 | Poseida Therapeutics, Inc. | Genetically modified cells and methods of use thereof |
| WO2023209649A1 (en) * | 2022-04-29 | 2023-11-02 | Seqirus, Inc. | Method of dna linearization |
| WO2024007010A2 (en) * | 2022-06-30 | 2024-01-04 | Demeetra Agbio, Inc. | Gene editing compositions and methods of use thereof |
| EP4605525A1 (en) | 2022-10-21 | 2025-08-27 | Keygene N.V. | Rna transfection in plant cells with modified rna |
| CN120225666A (zh) | 2022-11-21 | 2025-06-27 | 艾欧凡斯生物治疗公司 | 用于评估基因编辑的t细胞的增殖效力的方法 |
| EP4623072A2 (en) | 2022-11-21 | 2025-10-01 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024121354A1 (en) | 2022-12-08 | 2024-06-13 | Keygene N.V. | Duplex sequencing with covalently closed dna ends |
| EP4651943A1 (en) | 2023-01-20 | 2025-11-26 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| IL322198A (en) | 2023-01-20 | 2025-09-01 | Poseida Therapeutics Inc | Lipidoid compounds and related compositions and uses |
| CN121079405A (zh) * | 2023-02-21 | 2025-12-05 | 波西达治疗公司 | 用于基因组编辑的组合物和方法 |
| EP4669745A1 (en) * | 2023-02-21 | 2025-12-31 | Poseida Therapeutics, Inc. | COMPOSITIONS AND GENOMIC EDITING PROCESSES |
| WO2024209000A1 (en) | 2023-04-04 | 2024-10-10 | Keygene N.V. | Linkers for duplex sequencing |
| AU2024271748A1 (en) | 2023-05-17 | 2025-11-13 | Poseida Therapeutics, Inc. | Compositions targeting hbg1 and hbg2 and methods of use thereof |
| WO2025049925A2 (en) | 2023-09-01 | 2025-03-06 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025096980A1 (en) | 2023-11-02 | 2025-05-08 | Poseida Therapeutics, Inc. | Compositions targeting klkb1 and methods of use thereof |
| WO2025160432A1 (en) | 2024-01-26 | 2025-07-31 | Poseida Therapeutics, Inc. | Methods and compositions for enhancing in vivo persistence and potency of cell therapy |
| WO2025171237A1 (en) | 2024-02-08 | 2025-08-14 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025221789A1 (en) | 2024-04-16 | 2025-10-23 | Poseida Therapeutics, Inc. | Compositions and methods for use in car/tcr cell therapies |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5380831A (en) | 1986-04-04 | 1995-01-10 | Mycogen Plant Science, Inc. | Synthetic insecticidal crystal protein gene |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| TW261517B (enExample) | 1991-11-29 | 1995-11-01 | Mitsubishi Shozi Kk | |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
| US5645829A (en) | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5639642A (en) | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US7285416B2 (en) | 2000-01-24 | 2007-10-23 | Gendaq Limited | Regulated gene expression in plants |
| DE19524720A1 (de) | 1995-07-12 | 1997-01-16 | Hoechst Ag | Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3" |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| JP4216350B2 (ja) | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | 動物細胞感染用の組換えｄｎａウイルスベクター |
| US5789147A (en) | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
| US5869040A (en) | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
| US5928914A (en) | 1996-06-14 | 1999-07-27 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Methods and compositions for transforming cells |
| WO2000002996A2 (en) | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| CA2246005A1 (en) | 1998-10-01 | 2000-04-01 | Hsc Research And Development Limited Partnership | Hybrid genes for gene therapy in erythroid cells |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| JP2003500051A (ja) | 1999-05-25 | 2003-01-07 | パノラマ リサーチ，インコーポレイティド | 相互作用活性化タンパク質 |
| ATE353361T1 (de) | 2000-04-28 | 2007-02-15 | Sangamo Biosciences Inc | Gezielten modifikation der chromatinstruktur |
| AU2002243645A1 (en) | 2001-01-22 | 2002-07-30 | Sangamo Biosciences, Inc. | Zinc finger proteins for dna binding and gene regulation in plants |
| US7700754B1 (en) * | 2001-06-05 | 2010-04-20 | Masahiro Hiraoka | Polypeptide for unstabilizing protein in cells under aerobic conditions and DNA encoding the same |
| US20030138850A1 (en) | 2001-10-18 | 2003-07-24 | Ekkehard Mossner | Selecting for antibody-antigen interactions in bacteria cells by employing a protein fragment complementation assay |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| US8021849B2 (en) | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
| US20060252140A1 (en) | 2005-04-29 | 2006-11-09 | Yant Stephen R | Development of a transposon system for site-specific DNA integration in mammalian cells |
| US7790379B2 (en) | 2005-05-19 | 2010-09-07 | Universite De Geneve | Mapping of proteins along chromatin by chromatin cleavage |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| JP2007159512A (ja) | 2005-12-15 | 2007-06-28 | Institute Of Physical & Chemical Research | Ｉｉｓ型制限酵素を用いる翻訳終止コドンの除去方法 |
| WO2007122511A2 (en) | 2006-04-21 | 2007-11-01 | Mab-Factory Gmbh | Antibody-rnase-conjugate |
| WO2008130629A2 (en) | 2007-04-19 | 2008-10-30 | Codon Devices, Inc. | Engineered nucleases and their uses for nucleic acid assembly |
| AU2008302397A1 (en) | 2007-09-17 | 2009-03-26 | Affomix Corporation | Increasing specificity in a scFv screen using dual bait reporters |
| EP2401298A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
| CA2751000A1 (en) | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| EP2571512B1 (en) | 2010-05-17 | 2017-08-23 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
| WO2012093833A2 (en) | 2011-01-03 | 2012-07-12 | Toolgen Incorporation | Genome engineering via designed tal effector nucleases |
| CN103328507B (zh) | 2011-01-06 | 2016-09-07 | 康普里斯股份有限公司 | Alphabody文库及其产生方法 |
| US9499592B2 (en) | 2011-01-26 | 2016-11-22 | President And Fellows Of Harvard College | Transcription activator-like effectors |
| JP5996630B2 (ja) | 2011-04-05 | 2016-09-21 | セレクティスＣｅｌｌｅｃｔｉｓ | コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用 |
| EP2522726A1 (en) | 2011-05-12 | 2012-11-14 | Fundació Privada Centre de Regulació Genòmica (CRG) | Zinc finger nucleases for p53 editing |
| WO2012158986A2 (en) | 2011-05-17 | 2012-11-22 | Transposagen Biopharmaceuticals, Inc. | Methods for site-specific genetic modification in stem cells using xanthomonas tal nucleases (xtn) for the creation of model organisms |
| US20140304847A1 (en) | 2011-06-07 | 2014-10-09 | Ralf Kühn | Recombination efficiency by inhibition of nhej dna repair |
| WO2012168304A1 (en) | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Protein having nuclease activity, fusion proteins and uses thereof |
| UA115772C2 (uk) | 2011-12-16 | 2017-12-26 | Таргітджин Байотекнолоджиз Лтд | Композиція програмованого нуклеопротеїнового молекулярного комплексу і спосіб модифікування заданої послідовності нуклеїнової кислоти-мішені |
| US20130274129A1 (en) | 2012-04-04 | 2013-10-17 | Geneart Ag | Tal-effector assembly platform, customized services, kits and assays |
| WO2013177231A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| MY189533A (en) * | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| US9181535B2 (en) * | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| DK2911687T3 (da) | 2012-10-26 | 2019-05-13 | Univ Brussel Vrije | Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf |
| ES2778033T3 (es) | 2012-11-16 | 2020-08-07 | Poseida Therapeutics Inc | Enzimas específicas de sitio y métodos de uso |
| AU2013355214B2 (en) * | 2012-12-06 | 2017-06-15 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20150044772A1 (en) * | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
| SG11201609211VA (en) | 2014-03-05 | 2016-12-29 | Nat Univ Corp Univ Kobe | Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same |
| JP2017518083A (ja) | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス， インコーポレイテッド | ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物 |
| JP2017518082A (ja) * | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス， インコーポレイテッド | ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用 |
| CN104450785A (zh) * | 2014-12-08 | 2015-03-25 | 复旦大学 | 使用编码靶向核酸内切酶附着体载体的基因组编辑方法及试剂盒 |
-
2016
- 2016-06-16 DK DK16733813.6T patent/DK3310909T3/da active
- 2016-06-16 US US15/580,675 patent/US11473082B2/en active Active
- 2016-06-16 EP EP16733813.6A patent/EP3310909B1/en active Active
- 2016-06-16 ES ES16733813T patent/ES2886599T3/es active Active
- 2016-06-16 JP JP2018517674A patent/JP2018521689A/ja not_active Ceased
- 2016-06-16 CA CA2989827A patent/CA2989827C/en active Active
- 2016-06-16 CN CN201680047154.3A patent/CN108026519A/zh active Pending
- 2016-06-16 AU AU2016278226A patent/AU2016278226B2/en active Active
- 2016-06-16 PT PT167338136T patent/PT3310909T/pt unknown
- 2016-06-16 KR KR1020187001436A patent/KR102637402B1/ko active Active
- 2016-06-16 WO PCT/US2016/037922 patent/WO2016205554A1/en not_active Ceased
- 2016-06-16 EP EP21177979.8A patent/EP3929286A1/en active Pending
-
2021
- 2021-05-10 JP JP2021079698A patent/JP7170090B2/ja active Active
- 2021-08-31 JP JP2021141109A patent/JP2021182942A/ja not_active Withdrawn
- 2021-10-18 AU AU2021250992A patent/AU2021250992B2/en active Active
-
2022
- 2022-08-25 US US17/822,240 patent/US20230257737A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521689A5 (enExample) | ||
| JP7550816B2 (ja) | シークエンシングによって評価されるゲノムワイドでバイアスのないＤＳＢの同定（ＧＵＩＤＥ－Ｓｅｑ） | |
| Modzelewski et al. | Mammalian genome innovation through transposon domestication | |
| Sendler et al. | Stability, delivery and functions of human sperm RNAs at fertilization | |
| Wang et al. | Cas12a base editors induce efficient and specific editing with low DNA damage response | |
| Galupa et al. | A conserved noncoding locus regulates random monoallelic Xist expression across a topological boundary | |
| Perera et al. | The role of environmental exposures and the epigenome in health and disease | |
| Bustamante-Marin et al. | Lack of GAS2L2 causes PCD by impairing cilia orientation and mucociliary clearance | |
| US10640820B2 (en) | Methods relating to the detection of recurrent and non-specific double strand breaks in the genome | |
| A. Lea et al. | Human germline genome editing | |
| Frock et al. | Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases | |
| Castillo et al. | Human sperm chromatin epigenetic potential: genomics, proteomics, and male infertility | |
| ES2819277T3 (es) | Secuenciación dirigida y filtrado de UID | |
| AU2024219947A1 (en) | High-Throughput Single-Cell Sequencing With Reduced Amplification Bias | |
| CN104357918B (zh) | 血浆游离dna文库的构建方法 | |
| MX2018001617A (es) | Composiciones de crispr-cas9 diseñados y metodos de uso. | |
| CN111454951A (zh) | 以核酸为靶的核酸的组合物和方法 | |
| Liu et al. | TDG is a pig-specific epigenetic regulator with insensitivity to H3K9 and H3K27 demethylation in nuclear transfer embryos | |
| Suzuki et al. | Identical sets of methylated and nonmethylated genes in Ciona intestinalis sperm and muscle cells | |
| Cañestro | Two rounds of whole-genome duplication: evidence and impact on the evolution of vertebrate innovations | |
| Claeys Bouuaert et al. | Hsmar1 transposition is sensitive to the topology of the transposon donor and the target | |
| JP2023503395A (ja) | １種以上の標的特異的プログラム可能ヌクレアーゼの細胞におけるオフターゲット活性を明らかにするための、ｉｎ ｖｉｔｒｏでの真の不偏的なアッセイ（Ａｂｎｏｂａ－Ｓｅｑ） | |
| Yang et al. | Germ cell-specific eIF4E1b regulates maternal mRNA translation to ensure zygotic genome activation | |
| Bertozzi et al. | A spontaneous genetically induced epiallele at a retrotransposon shapes host genome function | |
| Kuo et al. | TALEN‐mediated gene editing of the thrombospondin‐1 locus in axolotl |